BACKGROUND: Glycoprotein (GP)VI is the major signaling receptor for collagen on platelets and signals via the associated FcRgamma-chain, which has an immunoreceptor tyrosine-containing activation motif (ITAM). OBJECTIVE: To determine why GPVI-FcRgamma signals poorly, or not at all, in response to collagen in hematopoietic cell lines, despite robust responses to the GPVI-reactive snake venom toxin convulxin. METHODS AND RESULTS: Using a nuclear factor of activated T-cells (NFAT) transcriptional reporter assay, a sensitive readout for sustained ITAM signaling, we demonstrate collagen-induced GPVI-FcRgamma signaling in hematopoietic cell lines. This is accompanied by relatively weak but sustained protein tyrosine phosphorylation, in contrast to the stronger but transient response to convulxin. Sustained signaling by collagen is also observed in platelets and is necessary for the maintenance of spreading on collagen. Finally, in cell lines, the inhibitory collagen receptor leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1), which is not expressed on platelets but is present on most hematopoietic cells, inhibits GPVI responses to collagen but not convulxin. CONCLUSION: The inability of previous studies to readily detect GPVI collagen signaling in cell lines is probably because of the weak but sustained nature of the signal and the presence of the inhibitory collagen receptor LAIR-1. In platelets, we propose that GPVI-FcRgamma has evolved to transmit sustained signals in order to maintain spreading over several hours, as well as facilitating rapid activation through release of feedback agonists and integrin activation. The establishment of a cell line NFAT assay will facilitate the molecular dissection of GPVI signaling and the identification of GPVI antagonists in drug discovery.
BACKGROUND: Glycoprotein (GP)VI is the major signaling receptor for collagen on platelets and signals via the associated FcRgamma-chain, which has an immunoreceptor tyrosine-containing activation motif (ITAM). OBJECTIVE: To determine why GPVI-FcRgamma signals poorly, or not at all, in response to collagen in hematopoietic cell lines, despite robust responses to the GPVI-reactive snake venom toxin convulxin. METHODS AND RESULTS: Using a nuclear factor of activated T-cells (NFAT) transcriptional reporter assay, a sensitive readout for sustained ITAM signaling, we demonstrate collagen-induced GPVI-FcRgamma signaling in hematopoietic cell lines. This is accompanied by relatively weak but sustained protein tyrosine phosphorylation, in contrast to the stronger but transient response to convulxin. Sustained signaling by collagen is also observed in platelets and is necessary for the maintenance of spreading on collagen. Finally, in cell lines, the inhibitory collagen receptor leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1), which is not expressed on platelets but is present on most hematopoietic cells, inhibits GPVI responses to collagen but not convulxin. CONCLUSION: The inability of previous studies to readily detect GPVI collagen signaling in cell lines is probably because of the weak but sustained nature of the signal and the presence of the inhibitory collagen receptor LAIR-1. In platelets, we propose that GPVI-FcRgamma has evolved to transmit sustained signals in order to maintain spreading over several hours, as well as facilitating rapid activation through release of feedback agonists and integrin activation. The establishment of a cell line NFAT assay will facilitate the molecular dissection of GPVI signaling and the identification of GPVI antagonists in drug discovery.
Authors: Eelo Gitz; Alice Y Pollitt; Jerney J Gitz-Francois; Osama Alshehri; Jun Mori; Samantha Montague; Gerard B Nash; Michael R Douglas; Elizabeth E Gardiner; Robert K Andrews; Christopher D Buckley; Paul Harrison; Steve P Watson Journal: Blood Date: 2014-08-22 Impact factor: 22.113
Authors: Tessa A M Steevels; Geertje H A Westerlaken; Marloes R Tijssen; Paul J Coffer; Peter J Lenting; Jan Willem N Akkerman; Linde Meyaard Journal: Haematologica Date: 2010-08-16 Impact factor: 9.941
Authors: Chek Ziu Koo; Neale Harrison; Peter J Noy; Justyna Szyroka; Alexandra L Matthews; Hung-En Hsia; Stephan A Müller; Johanna Tüshaus; Joelle Goulding; Katie Willis; Clara Apicella; Bethany Cragoe; Edward Davis; Murat Keles; Antonia Malinova; Thomas A McFarlane; Philip R Morrison; Hanh T H Nguyen; Michael C Sykes; Haroon Ahmed; Alessandro Di Maio; Lisa Seipold; Paul Saftig; Eleanor Cull; Christos Pliotas; Eric Rubinstein; Natalie S Poulter; Stephen J Briddon; Nicholas D Holliday; Stefan F Lichtenthaler; Michael G Tomlinson Journal: J Biol Chem Date: 2020-02-28 Impact factor: 5.157
Authors: Craig E Hughes; Alice Y Pollitt; Jun Mori; Johannes A Eble; Michael G Tomlinson; John H Hartwig; Christopher A O'Callaghan; Klaus Fütterer; Steve P Watson Journal: Blood Date: 2010-02-12 Impact factor: 22.113
Authors: Peter J Lenting; Geertje H A Westerlaken; Cécile V Denis; Jan Willem Akkerman; Linde Meyaard Journal: PLoS One Date: 2010-08-13 Impact factor: 3.240
Authors: Jun Mori; Andrew C Pearce; Jennifer C Spalton; Beata Grygielska; Johannes A Eble; Michael G Tomlinson; Yotis A Senis; Steve P Watson Journal: J Biol Chem Date: 2008-10-27 Impact factor: 5.157
Authors: Craig E Hughes; Uvaraj P Radhakrishnan; Marie Lordkipanidzé; Stuart Egginton; Johannes M Dijkstra; Pudur Jagadeeswaran; Stephen P Watson Journal: PLoS One Date: 2012-12-21 Impact factor: 3.240
Authors: Deya Cherpokova; Markus Bender; Martina Morowski; Peter Kraft; Michael K Schuhmann; Sarah M Akbar; Cheryl S Sultan; Craig E Hughes; Christoph Kleinschnitz; Guido Stoll; Leonard L Dragone; Steve P Watson; Michael G Tomlinson; Bernhard Nieswandt Journal: Blood Date: 2014-10-09 Impact factor: 22.113